Ordering
Available Variants10 mg
CHA.83964-10mg
Price
€106.40
Available – Dispatch in 14 days
50 mg
CHA.83964-50mg
Price
€331.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.83964-10mg | €106.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.83964-50mg | €331.20 |
≥98% (HPLC), powder, Estrogen receptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H29NO2 |
|---|---|
| CAS Number | 68392-35-8 |
| Molecular Weight | 387.51 |
| UNSPSC Code | 51111800 |
| PubChem Substance ID | 24895736 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 300 |
| Storage condition | desiccated, protect from light |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 + H312 + H332,H315,H319,H361fd |
| pcodes | P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
4-Hydroxytamoxifen, with the CAS number 68047-06-3, is a metabolite of the selective estrogen receptor modulator tamoxifen. It is primarily formed through the hepatic metabolism of tamoxifen, mediated by the cytochrome P450 enzyme system. As a result of this metabolic process, 4-hydroxytamoxifen exhibits a higher affinity for estrogen receptors compared to its parent compound, thereby contributing significantly to the therapeutic effects of tamoxifen. The compound has been shown to act as an estrogen receptor antagonist in breast tissue, which is beneficial in the treatment and prevention of breast cancer. Furthermore, research has demonstrated that 4-hydroxytamoxifen plays a crucial role in the anti-estrogenic activity of tamoxifen, making it an important area of study in the field of endocrinology and oncology. Its mechanism of action and pharmacological properties continue to be the subject of ongoing scientific investigation.
